Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT05003063 |
| Other study ID # |
2018-10-11532 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
Early Phase 1
|
| First received |
|
| Last updated |
|
| Start date |
February 4, 2021 |
| Est. completion date |
August 2, 2021 |
Study information
| Verified date |
August 2021 |
| Source |
University of California, Berkeley |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
This study in, healthy human subjects using fMRI and MRS (magnetic resonance spectroscopy)
characterizes, how attention and acetylcholine affect visual perception and the brain's
representation of the visual environment. Levels of acetylcholine in the cerebral cortex will
be enhanced by administration of donepezil, an inhibitor of acetylcholinesterase. Half the
subjects will receive donepezil and other half will receive placebo.
Description:
The long-term objective of this project is to characterize how attention and acetylcholine
affect visual perception and the brain's representation of the visual environment.
Acetylcholine is a naturally occurring neurotransmitter, and acetylcholine release is
elevated during periods of sustained attention. Both acetylcholine and attention enhance
aspects of visual perception, but the underlying brain mechanisms are poorly understood. The
proposed work will address these questions in healthy human subjects by using functional
magnetic resonance imaging (fMRI) and MRS (magnetic resonance spectroscopy) to measure the
brain's responses to visual stimuli. Our previous studies have shown that increasing levels
of acetylcholine in the brain enhances the spatial resolution of the brain's representation
of the visual environment. The proposed research will document exactly which brain areas
mediate this effect of acetylcholine and will also characterize the effects of attention on
these measures of spatial resolution in the brain.
The technique of fMRI (functional magnetic resonance imaging) and MRS (magnetic resonance
spectroscopy), both subtypes of MRI, will be employed to measure brain activity in different
brain areas while subjects are performing a visual attention task. Levels of acetylcholine in
the cerebral cortex will be enhanced by administration of donepezil, an inhibitor of
acetylcholinesterase, the enzyme that metabolizes acetylcholine. Moreover, the technique of
MRS will be employed to locally quantify the levels of acetylcholine in different brain
areas.
In addition to providing information about how attention is represented in the brain and how
it affects processing of visual stimuli, the present experiments should also shed light on
the function of the cholinergic projection from the basal forebrain to the cerebral cortex.
As this projection is thought to be selectively impaired in Alzheimer's disease, knowledge
concerning its function in the healthy brain may be useful for understanding the etiology of
this disease and for development of appropriate therapies.
BEHAVIORAL PHARMACOLOGY:
Sessions:
Subjects will perform 6 behavioral sessions over several days outside the scanner, split into
two experimental parts. There will be 2 baseline sessions without donepezil/placebo and 4
testing sessions with donepezil/placebo. Each behavioral (outside the scanner) session will
last 1-2 hours. During the testing session, subjects will be given one pill of (2.5 or 5 or
10mg) donepezil or placebo per session. The choice of the pill will be determined by the flip
of a coin. The drug dosage (2.5 or 5 or 10mg) will be determined so as to ensure that there
are equal number of participants per drug dosage. The pill (drug or placebo) not selected for
the first experimental session in a pair will be administered during the second experimental
session.
Task:
A typical cognitive task will involve presentation of images or words on a computer monitor
or sounds through headphones. The subjects are asked to respond to certain stimuli by
pressing a button. All stimuli are presented at a comfortable level. The cognitive task
performed during the behavioral is an object-tracking/target detection paradigm in which
subjects indicate whether a target is presented or not on each experimental trial. The
target, when it is presented, is a visual stimulus at the threshold of detectability. On some
trials, subjects will receive cues indicating target location and/or features that will
facilitate target detection. Subjects will be asked to report by pressing a button on a
response box. Subjects will receive breaks every 5-10 minutes or more frequently if they
desire.
MRI AND PHARMACOLOGY:
Sessions:
For experiments involving MRI, there will be a total of 6 sessions across several days, split
into two experimental parts. There will be two baseline MRI session without donepezil/placebo
and 4 testing sessions (two donepezil, two placebo). Subjects will be given one pill of (2.5
or 5 or 10mg) donepezil or placebo per session. The choice of the pill will be determined by
the flip of a coin. The pill not selected for the first experimental part will be
administered during the second experimental part.
For MRI experiments, the experimenter will escort the subject to the Brain Imaging Center in
Li Ka Shing about 2.5 hours after pill administration, and fMRI measurements will begin
approximately 3 hours after pill administration. The MRI sessions typically take 1-2.5 hours,
and the subject is given frequent breaks. The subject may stop the experiment at any time.
Subjects undergoing MRI scanning will be asked to lie on their back in the MRI scanner.
Before being scanned, a MRI imaging coil made of plastic will be placed around the subject's
head. The subject will not come into contact with the coil during the experiment. Foam pads
will be placed around the subject's head to limit head movement during the study.
Task:
A typical cognitive task will involve presentation of images or words on a computer monitor
or sounds through headphones. The subjects are asked to respond to certain stimuli by
pressing a button. All stimuli are presented at a comfortable level. The cognitive task
performed during the behavioral is an object-tracking/target detection paradigm in which
subjects indicate whether a target is presented or not on each experimental trial. The
target, when it is presented, is a visual stimulus at the threshold of detectability. On some
trials, subjects will receive cues indicating target location and/or features that will
facilitate target detection. Subjects will be asked to report by pressing a button on a
response box. Subjects will receive breaks every 5-10 minutes or more frequently if they
desire.
